<DOC>
	<DOC>NCT01100502</DOC>
	<brief_summary>This is a randomized, double-blind, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) and best supportive care (BSC) compared to placebo and BSC in treatment of residual Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT).</brief_summary>
	<brief_title>A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Patients with HL who have received ASCT in the previous 3045 days Patients at high risk of residual HL post ASCT Histologicallyconfirmed HL ECOG of 0 or 1 Adequate organ function Previous treatment with brentuximab vedotin Previously received an allogeneic transplant Patients who were determined to have a best clinical response of progressive disease with salvage treatment immediately prior to ASCT History of another primary malignancy that has not been in remission for at least 3 years Post ASCT or current therapy with other systemic antineoplastic or investigational agents</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Antigens, CD30</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antibodies, Monoclonal</keyword>
	<keyword>Disease, Hodgkin</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Monomethylauristatin E</keyword>
</DOC>